Physicochemical Properties
| Molecular Formula | C25H21IN2O |
| Molecular Weight | 492.35 |
| Exact Mass | 492.069 |
| CAS # | 2252162-81-3 |
| PubChem CID | 145982772 |
| Appearance | White to yellow solid powder |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 1 |
| Heavy Atom Count | 29 |
| Complexity | 628 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | C[N+]1C2=CC=CC=C2C(N)=C2C(/C(=C/C3C4C(C=CC=3)=CC=CC=4)/CCC=12)=O.[I-] |
| InChi Key | ZPWPPSSEAGEKIT-FLNCGGNMSA-N |
| InChi Code | InChI=1S/C25H20N2O.HI/c1-27-21-12-5-4-11-20(21)24(26)23-22(27)14-13-18(25(23)28)15-17-9-6-8-16-7-2-3-10-19(16)17;/h2-12,15,26H,13-14H2,1H3;1H/b18-15+; |
| Chemical Name | (2E)-9-amino-10-methyl-2-(naphthalen-1-ylmethylidene)-3,4-dihydroacridin-10-ium-1-one;iodide |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | Kd: 160 μM (Aβ1-42)[1]. Kd: 337 μM (tau)[1] |
| ln Vitro | The tau aggregation foci are greatly reduced by Aβ/tau aggregation-IN-1 (1 μM; 24 hours; HEK-293 T cells)[1]. Aβ/tau aggregation-IN-1 efficiently inhibits tau aggregation by 71.2%–101.8% and Aβ1–42 aggregation by 84.7%–99.5% when the quinolone ring is N-methylated. Aβ/tau aggregation-IN-1 prevents the production of β-sheets, which in turn prevents self-induced Aβ1-42 aggregation. Aβ/tau aggregation-IN-1 demonstrates specific binding properties with tau and Aβ1-42. Aβ/tau aggregation-IN-1 with Aβ1-42 has a KD value of 160 μM. Aβ/tau aggregation-IN-1 with tau has a KD value of 337 μM. Through noncovalent interactions, tau and Aβ1-42 are interacting with Aβ/tau aggregation-IN-1[1]. |
| Cell Assay |
Immunofluorescence[1] Cell Types: HEK-293 T cells Tested Concentrations: 1 μM Incubation Duration: 24 hrs (hours) Experimental Results: Dramatically declined the tau aggregation foci. |
| References |
[1]. Synthesis and evaluation of 1,2,3,4-tetrahydro-1-acridone analogues as potential dual inhibitors for amyloid-beta and tau aggregation. Bioorg Med Chem. 2018;26(16):4693-4705. |
Solubility Data
| Solubility (In Vitro) | DMSO: 33.33 mg/mL (67.70 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (2.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (2.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0311 mL | 10.1554 mL | 20.3108 mL | |
| 5 mM | 0.4062 mL | 2.0311 mL | 4.0622 mL | |
| 10 mM | 0.2031 mL | 1.0155 mL | 2.0311 mL |